Literature DB >> 34050756

Maternal Midpregnancy Leptin and Adiponectin Levels as Predictors of Autism Spectrum Disorders: A Prenatal Cohort Study.

Kyoung Eun Joung1,2, Sheryl L Rifas-Shiman3, Emily Oken3,4, Christos S Mantzoros2,5,6.   

Abstract

CONTEXT: Autism spectrum disorders (ASDs) are a group of conditions characterized by impaired social function and repetitive behaviors. Their etiology is largely unknown.
OBJECTIVE: This work aims to examine the associations of maternal second-trimester and cord blood leptin and adiponectin levels with ASDs in offspring.
METHODS: We used data from 1164 mother-child pairs enrolled in Project Viva, a prospective prebirth cohort. We used logistic regression analysis to examine the associations of leptin and adiponectin levels in maternal second-trimester blood and cord blood obtained at birth with ASDs. Additionally, we examined the association of maternal prepregnancy body mass index (BMI) as an exposure. Main outcome measures included doctor-diagnosed ASDs reported by mothers using questionnaires in midchildhood and early adolescence.
RESULTS: The cumulative incidence of ASDs was 3.4%. Maternal prepregnancy BMI (per 5 points) was positively associated with ASDs in a logistic regression model adjusted for maternal race/ethnicity, education, smoking status and child sex (adjusted odds ratio [OR] 1.38; 95% CI, 1.06-1.79). Higher second-trimester adiponectin was associated with lower odds of ASD in offspring (unadjusted OR 0.49; 95% CI, 0.30-0.78; and OR 0.54; 95% CI, 0.32-0.91 after adjusting for maternal race/ethnicity, education, child sex, OR 0.55; 95% CI, 0.33-0.93 after adjusting for BMI, gestational weight gain, gestational diabetes, and smoking status). Maternal leptin and cord blood leptin and adiponectin levels were not associated with ASDs.
CONCLUSION: Prepregnancy BMI and adiponectin during pregnancy may be useful as a tool to monitor the risk of autism. Increasing adiponectin levels prenatally may play a role in the prevention of ASDs.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  BMI; adiponectin; autism spectrum disorder; leptin; pregnancy

Mesh:

Substances:

Year:  2021        PMID: 34050756      PMCID: PMC8475238          DOI: 10.1210/clinem/dgab378

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   6.134


  39 in total

1.  The role of epigenetic modifications in neurodevelopmental disorders: A systematic review.

Authors:  Lorenza Dall'Aglio; Taulant Muka; Charlotte A M Cecil; Wichor M Bramer; Michael M P J Verbiest; Jana Nano; Andrea Cortes Hidalgo; Oscar H Franco; Henning Tiemeier
Journal:  Neurosci Biobehav Rev       Date:  2018-07-29       Impact factor: 8.989

Review 2.  Beyond infection - Maternal immune activation by environmental factors, microglial development, and relevance for autism spectrum disorders.

Authors:  Staci D Bilbo; Carina L Block; Jessica L Bolton; Richa Hanamsagar; Phuong K Tran
Journal:  Exp Neurol       Date:  2017-07-08       Impact factor: 5.330

3.  Development of the human fetal hippocampal formation during early second trimester.

Authors:  Xinting Ge; Yonggang Shi; Junning Li; Zhonghe Zhang; Xiangtao Lin; Jinfeng Zhan; Haitao Ge; Junhai Xu; Qiaowen Yu; Yuan Leng; Gaojun Teng; Lei Feng; Haiwei Meng; Yuchun Tang; Fengchao Zang; Arthur W Toga; Shuwei Liu
Journal:  Neuroimage       Date:  2015-06-26       Impact factor: 6.556

4.  Plasma Levels of Leptin and Adiponectin in Fragile X Syndrome.

Authors:  Małgorzata Zofia Lisik; Ewa Gutmajster; Aleksander L Sieroń
Journal:  Neuroimmunomodulation       Date:  2016-12-01       Impact factor: 2.492

5.  CDC growth charts: United States.

Authors:  R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson
Journal:  Adv Data       Date:  2000-06-08

6.  Enduring consequences of maternal obesity for brain inflammation and behavior of offspring.

Authors:  Staci D Bilbo; Verne Tsang
Journal:  FASEB J       Date:  2010-02-02       Impact factor: 5.191

7.  Cord blood leptin and adiponectin as predictors of adiposity in children at 3 years of age: a prospective cohort study.

Authors:  Christos S Mantzoros; Sheryl L Rifas-Shiman; Catherine J Williams; Jessica L Fargnoli; Theodoros Kelesidis; Matthew W Gillman
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

8.  Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways.

Authors:  Jane E Ramsay; William R Ferrell; Lynne Crawford; A Michael Wallace; Ian A Greer; Naveed Sattar
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

Review 9.  Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction.

Authors:  Arunkumar E Achari; Sushil K Jain
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

10.  Maternal Immune Activation Causes Behavioral Impairments and Altered Cerebellar Cytokine and Synaptic Protein Expression.

Authors:  Gurudutt Pendyala; Shinnyi Chou; Yoosun Jung; Pierluca Coiro; Elizabeth Spartz; Ragunathan Padmashri; Ming Li; Anna Dunaevsky
Journal:  Neuropsychopharmacology       Date:  2017-01-19       Impact factor: 7.853

View more
  2 in total

1.  C1q/TNF-related protein-1: Potential biomarker for early diagnosis of autism spectrum disorder.

Authors:  Hamed Raeisy; Paria Bayati; Farshid Noorbakhsh; Mitra Hakim Shooshtari; Mehrdad Eftekhar Ardebili; Mehdi Shekarabi; Nazanin Mojtabavi
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.219

2.  Associations Among Maternal Metabolic Conditions, Cord Serum Leptin Levels, and Autistic Symptoms in Children.

Authors:  Toshiki Iwabuchi; Nagahide Takahashi; Tomoko Nishimura; Md Shafiur Rahman; Taeko Harada; Akemi Okumura; Hitoshi Kuwabara; Shu Takagai; Yoko Nomura; Hideo Matsuzaki; Norio Ozaki; Kenji J Tsuchiya
Journal:  Front Psychiatry       Date:  2022-02-03       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.